Carol Gallagher

CAROL GALLAGHER joined Calistoga Pharmaceuticals, Inc., in September 2008 as
Chief Executive Officer. She brings nearly 20 years’ experience in business and
drug development at large and small biopharmaceutical companies. Prior to
Calistoga, Dr. Gallagher was President and CEO of Metastatix, a private oncology
company. In 2006, she served as Senior Vice President of Corporate Development
for Anadys Pharmaceuticals, where she directed business development and
commercial and strategic planning. From 2003 to 2006, she worked at CancerVax,
where she served as Vice President of Product Planning. At CancerVax, Dr.
Gallagher was part of the management team that executed the Canvaxin license
with Serono and the subsequent reverse merger with Micromet, Inc. Beginning in
2002, Dr. Gallagher led the Rituxan collaboration and oncology marketing at
Biogen Idec. During her tenure at Biogen Idec, Dr. Gallagher led the Rituxan
team when oncology sales first surpassed $1 billion and the rheumatoid arthritis
and multiple sclerosis development programs were designed. Dr. Gallagher also
led oncology and ophthalmology global marketing planning at Pfizer, joining
Pfizer through the acquisition of Warner Lambert and Agouron Pharmaceuticals.
Dr. Gallagher began her career in sales and marketing at Eli Lilly and also held
various sales and marketing roles at Amgen prior to joining Agouron
Pharmaceuticals in 1997. She received Bachelor of Science and Doctor of Pharmacy
degrees from the College of Pharmacy at the University of Kentucky.